Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
CTR20221519Phase 2Completed
- Sponsor
- Incyte
- Start
- Sep 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab, lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Incyte. Started Sep 2022; status: completed.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20221519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221519.